Navigation Links
Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
Date:6/24/2013

LONDON, June 24, 2013 /PRNewswire/ --

On Friday, June 21, 2013, shares in drug manufacturers ended on a mixed note, tracking the broader market which also finished mixed after witnessing losses in two successive trading sessions. The major movers included Pharmacyclics Inc. (NASDAQ: PCYC), United Therapeutics Corporation (NASDAQ: UTHR), Impax Laboratories Inc. (NASDAQ: IPXL), and Star Scientific Inc. (NASDAQ: STSI). All these companies are tracked by AAAResearchReports.com. Free technical research on PCYC, UTHR, IPXL, and STSI can be downloaded upon sign up at

http://www.aaaresearchreports.com/register/  

Shares in Pharmacyclics Inc. ended slightly lower on Friday, extending their losses from previous trading sessions. The company's shares oscillated between $78.23 and $81.96 before closing the day at $81.00, down 0.36%. A total of 1.05 million shares were traded which is above the daily average volume of 739,954. Pharmacyclics' shares have now declined by over 8.20% in the last three sessions. Sign up today to read free research report on PCYC at:

http://www.AAAResearchReports.com/PCYC062413.pdf

United Therapeutics Corporation's stock posted modest gains on Friday, reversing some of its losses from previous market sessions. The company's shares ended the day at $63.34, up 0.19%, after trading between $62.78 and $64.55. A total of 818,292 shares were traded which is above the daily average volume of 567,754. United Therapeutics' shares have slipped by more than 3.50% in the last three trading sessions. However, despite the recent losses, the stock is still up 3.92% in the last three months. Register to download free technical analysis on UTHR at:

http://www.AAAResearchReports.com/UTHR062413.pdf

Shares in Impax Laboratories Inc. moved higher on Friday, paring some of its losses from its previous two trading sessions. The company's shares traded between $17.69 and $18.22 before finishing the day 0.72% higher at $18.09. A total of 1.54 million shares were traded which is above the daily average volume of 1.15 million. Impax's shares have now fallen more than 4% in the last three sessions. In the last three months, the stock has gained over 15.80%, thus outperforming the S&P 500. Additionally, shares of the company are currently trading slightly above their 50-day moving average. A free report on IPXL can be accessed by registering at:

http://www.AAAResearchReports.com/IPXL062413.pdf

Star Scientific Inc.'s stock rose sharply on Friday, closing 1.53% higher at $1.33 after trading between $1.24 and $1.33. A total of 1.73 million shares were traded which is above the daily average volume of 1.07 million. However, despite the sharp rise on Friday, the company's shares have fallen by 8.28% in the last three trading sessions. Moreover, the stock is also trading above its 50-day and 200-day moving average. Register with AAA Research Reports and download the research on STSI for free at:

http://www.AAAResearchReports.com/STSI062413.pdf

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


'/>"/>
SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
2. United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
3. Wysebridge Encourages Taking The Patent Bar Before Major Exam Changes Are Implemented
4. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
5. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
6. A Simple Guide to De-Risking Before Full Prescribing Information, New Life Science Webinar Hosted by Xtalks
7. Grab the Summer Promo Before It Cools Down by Conscires Agile Practices
8. Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCalls Microscope
9. Animal Husbandry Equipment Market in United States: Business Report 2011
10. Strategic Analysis of the Collagen Peptide Market in the United States
11. GDS International Combines Top Healthcare Executives in the United States for its 10th Anniversary NG Healthcare Summit in May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 Scientists propose ... inflammation and organ damage in Gaucher and maybe other ... risks and lower costs than current therapies. ... Hospital Medical Center , which also included investigators from ... , report their data Feb. 22. The study was ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the ... from around the world, is pleased to announce the launch of a new scholarship ... mathematics (STEM) fields. , This merit-based scholarship is open to all high school seniors, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in the FDA CDRH ... Drug Evaluation Staff has joined the company as an Expert Consultant. , In ...
(Date:2/21/2017)... ROCKVILLE, Md. , Feb. 21, 2017 Synthetic ... therapeutics designed to preserve the microbiome to protect and restore the ... for the year ended December 31, 2016 on Thursday, March 2, ... 4:30 p.m. EST. The dial-in information for the call is as ... ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile market ... prices have dropped dramatically. The quarterly average price of ... to $276 in Q4 2016.  There are now 120 ... of $116, up from just 28 a year ago ... According to Maxine Most , Acuity Market Intelligence ...
(Date:1/19/2017)... , January 19, 2017 According to a new report ... Forecast, 2014 - 2022," the global biometric sensor market is expected to garner ... 2022. In 2015, Asia-Pacific dominated the global market and ... sectors. Continue Reading ... ...
Breaking Biology News(10 mins):